---
run_id: halo-evidence-vs-diagnosis-validation-v10-famous-sources-supplied-02
created: 2026-05-24
eval_type: contradiction-preservation
case_id: halo-evidence-vs-diagnosis-validation-v10
benchmark_version: halo-evidence-vs-diagnosis-validation-v10-v1
model_condition: famous_sources_supplied
run_number: 2
model_name: gemma-4-31b-it-mlx:2
model_id: gemma-4-31b-it-mlx:2
model_snapshot: LM Studio MLX 8-bit model id lmstudio-community/gemma-4-31B-it-MLX-8bit; loaded_context_length 65536
runtime: LM Studio local OpenAI-compatible HTTP server; MLX runtime
provider: local
temperature: 0.7
top_p: 0.9
num_ctx: 65536
max_tokens: 1024
seed: 202
prompt_source: condition packet (famous_sources_supplied) - frozen added material plus frozen Advisor prompt; see run-packet.md
prompt_sha256: 61d771e2bff7fd2e18be1d2999d0f601760656e3e69b4622989ca7bffd3aff8e
source_packet: a name-level list of famous source titles and authors, then the frozen Advisor prompt; no claims, summaries, source cards, or tension card - see run-packet.md
source_packet_sha256: d057ad83d3f7bf7e5568fa060310fc46d54ebd76e09ae17c88d4f64128eb21dd
condition_packet_sha256: d057ad83d3f7bf7e5568fa060310fc46d54ebd76e09ae17c88d4f64128eb21dd
output_file: model-outputs/famous_sources_supplied-02.md
judge_model_id: pending - judge receipts recorded separately under judge-packet
judge_prompt_sha256: pending - judge receipts recorded separately under judge-packet
judge_independence: pending - judge receipts recorded separately under judge-packet
raw_model_output_public_safe: true
---

# Model Output - famous_sources_supplied (run 02)

## Condition

Benchmark version `halo-evidence-vs-diagnosis-validation-v10-v1`, condition `famous_sources_supplied`, run 2 of 8. Real local-model run: `gemma-4-31b-it-mlx:2` via lmstudio, seed 202, on the frozen condition packet.

## Output

**Recommendation:** Run the **Claim File Review**.

**Why:**
Your current success is an illusion created by "the halo effect": strong financial metrics (expansion bookings) are being attributed to product value, but the evidence suggests they are actually driven by pricing incentives (bundle discounts) and sales narratives (roadmap promises).

The critical risk is a "value gap." While usage is up, the data shows it is driven by managers (for training) rather than adjusters (for production). In the high-stakes regulated health-liability segment, the product is failing a fundamental requirement: explainability. If adjusters cannot justify a proposed action to a reviewer, the tool is a liability, not an asset.

The Usage Quality Sprint measures *if* people use it; the Commercial Cleanroom measures *if* people will pay for it. Only the Claim File Review reveals *why* they are abandoning it or overriding it. Before scaling or narrowing your segment, you must determine if DraftPath is solving the core problem or simply creating a new administrative burden that managers are masking during enablement.

**The strongest reason against it:**
It is the slowest and most labor-intensive of the three validation options. Unlike a dashboard (Sprint) or a pricing change (Cleanroom), manual file reviews are qualitative and small-sample. By the time you have a rigorous set of findings, the board may have already locked the budget based on the "strong quarter" momentum, making your findings a post-mortem rather than a pivot.

**Observable evidence that would change my mind:**
If the "regional carriers" who plan to remove DraftPath provide explicit, written feedback stating that their decision is based solely on the lack of a specific integration or a pricing dispute, rather than a failure of the tool’s utility. In that case, the problem is commercial (making the Commercial Cleanroom the priority) rather than a fundamental failure of product-market fit.
